Cladribine followed by autologous stem-cell transplantation in progressive multiple sclerosis.
We studied the safety of autologous peripheral blood stem-cell transplantation (PBSCT) in four patients with progressive multiple sclerosis. Clinical and magnetic resonance imaging outcomes were secondary end-points. Cladribine administration preceded filgrastim-primed PBSC collection, aiming for lymphocyte depletion. Conditioning was with antithymocyte globulin and cyclophosphamide. The procedure was well tolerated, but without obvious clinical benefit. The study was terminated when other therapeutic options with lower morbidity became available.
Grigg
A
A
Bone Marrow Transplant Service and Department of Neurosciences, The Royal Melbourne Hospital, Melbourne, Victoria 3050, Australia. andrew.grigg@mh.org.au
Tubridy
N J
NJ
Szer
J
J
Mitchell
P
P
Butzkueven
H
H
Shuttleworth
P
P
Kilpatrick
T
T
D000328:Adult; D017338:Cladribine / Q000627:therapeutic use*; D006801:Humans; D007166:Immunosuppressive Agents / Q000627:therapeutic use*; D008297:Male; D008875:Middle Aged; D020528:Multiple Sclerosis, Chronic Progressive / Q000628:therapy*; D033581:Stem Cell Transplantation; D013601:T-Lymphocytes / Q000187:drug effects; D016896:Treatment Outcome
D007166:Immunosuppressive Agents; D017338:Cladribine